PDCD1 and neoplasm: Accordingly, the recent therapeutic approaches, including CTLA-4 and PD-1 inhibitors (i.e., ICIs), aimed at reinforcing the molecular interaction between effector immune cells and tumor cells, have dramatically improved the outcome of metastatic melanoma patients 22-24.